Managing colorectal cancer in patients who progress on regorafenib

Cristina Smolenski, MD, Gustave Roussy, Villejuif, France, examines treatment options for patients who progress on trifluridine/tipiracil with bevacizumab or regorafenib. Fruquintinib has been identified as a promising strategy, where tumor angiogenesis can be inhibited. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.